This protocol applies to patients with stage II–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer who have completed primary platinum-based chemotherapy and achieved a complete or partial response. The maintenance phase that follows is clinically structured and selection-dependent.
Primary adjuvant systemic chemotherapy with a platinum-based regimen (such as Carboplatin/Paclitaxel, with or without Bevacizumab) was completed. The clinical goals of that line — complete response (no definitive evidence of disease) or partial response — were reached. This protocol defines the structured maintenance step that follows.
Maintenance in this setting involves targeted agents, including PARP inhibitor-based options. The specific approach is shaped by whether bevacizumab was part of primary chemotherapy, and by germline/somatic BRCA1/2 mutation status and homologous recombination findings. The full treatment algorithm, complete agent selection, and all dosing remain in the structured protocol.